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Transition metals are frequently used as cofactors for enzymes and oxygen-carrying proteins that take
advantage of their propensity to gain and lose single electrons. Metals are particularly important in mitochon-
dria, where they play essential roles in the production of ATP and detoxification of reactive oxygen species. At
the same time, transition metals (particularly Fe and Cu) can promote the formation of harmful radicals,
necessitating meticulous control of metal concentration and subcellular compartmentalization. We summa-
rize our current understanding of Fe and Cu in mammalian mitochondrial biology and discuss human
diseases associated with aberrations in mitochondrial metal homeostasis.Roles of Metals in Normal Mitochondrial Metabolism
Iron is the dominant metal in mitochondrial metabolism,
but copper has important roles (Figure 1). Fe-protoporphyrin
(heme), Fe-S clusters, and Cu are essential components of the
mitochondrial inner membrane complexes constituting the elec-
tron transport chain. Three of the four complexes of the electron
transport chain are physically associated (complexes I, III, and
IV) and provide most of the proton motive force (for review, see
Winge, 2012). Complex I (NADH dehydrogenase) contains eight
Fe-S clusters involved in the transfer of electrons from reduced
flavin mononucleotide (FMNH2) to ubiquinone (for review, see
Mimaki et al., 2012). Complex II (succinate dehydrogenase)
contains a heme b prosthetic group in its anchor domain, which
is essential for the structural integrity and function of the
complex. Electrons abstracted from dehydrogenation of succi-
nate are channeled through three Fe-S clusters ([2Fe-2S],
[4Fe-4S], and [3Fe-4S]) to reduce ubiquinone to ubiquinol.
Succinate dehydrogenase also participates in the tricarboxylic
acid (TCA) cycle, catalyzing the oxidation of succinate to fuma-
rate coupled to the reduction of ubiquinone (for review, see
Rutter et al., 2010). Complex III (ubiquinol: cytochrome c oxido-
reductase or cytochrome bc1 complex) catalyzes the reduction
of cytochrome c by oxidation of ubiquinol. Complex III contains
a cytochrome b subunit with two heme moieties, a cytochrome
c1 subunit with one heme, and a Rieske protein subunit
(UQCRFS1) with a [2Fe-2S] cluster. The heme moieties and the
Fe-S clusters participate in electron transfer. One electron from
each ubiquinone is transferred through the [2Fe-2S] Rieske
protein and cytochrome c1 to reduce soluble cytochrome c.
The second electron passes from one heme to the other of the
cytochrome b moiety as part of the Q cycle, resulting in proton
translocation across the inner membrane (for review, see Covian
and Trumpower, 2008). Complex IV (cytochrome c oxidase)
mediates the final step in the electron transport chain, catalyzing
the reduction of oxygen towater. It contains two heme amoieties
and two Cu centers, all of which participate in the electron
transfer process. Cytochrome c is oxidized, leading to electron
passage through the binuclear Cu center to one heme moiety,
then to a heme-copper center to reduce oxygen (for review,
see Yoshikawa et al., 2011).Some soluble mitochondrial enzymes also require metals.
Heme is a cofactor for sulfite oxidase, important for metabolism
of sulfur-containing amino acids. The TCA cycle enzyme aconi-
tase, which catalyzes the conversion of citrate to cis-aconitate,
contains a [4Fe-4S] cluster in its active site. Cu is found in
Cu-Zn superoxide dismutase (SOD1), which partially localizes
to the mitochondrial intermembrane space. A distinct enzyme,
Mn superoxide dismutase (SOD2), is found in the mitochondrial
matrix.
Mitochondria as a Site of Fe Cofactor Assembly
Mitochondria host complex biosynthetic pathways to produce
heme and Fe-S clusters for their own use and for use in other
cellular compartments.
Heme Biosynthesis
Most mitochondrial Fe is used to produce heme, an important
prosthetic group in a variety of cellular proteins, including elec-
tron transport chain complex subunits, hemoglobin, myoglobin,
and cytochromes. There are several physiologically relevant
forms of heme that differ in functional groups attached to the
protoporphyrin ring. Heme biosynthesis is a highly conserved
process dependent upon enzymatic steps both in the mito-
chondria and cytosol (Figure 2). Although the enzymatic reac-
tions are well understood, much remains to be learned about
transport of heme intermediates into and out of the mitochon-
drion. Heme synthesis begins with the formation of aminolevu-
linic acid (ALA) from glycine and succinyl-CoA, catalyzed by
aminolevulinic acid synthase (ALAS) in the mitochondrial matrix.
Mammals have two forms of ALAS: ALAS1, expressed ubiqui-
tously, and ALAS2, restricted to erythroid cells. ALA is exported
to the cytosol to be converted into porphobilinogen, hydroxy-
methylbilane, uroporphyrinogen III, and finally coproporphyrino-
gen III through a series of enzymatic reactions. Coproporphyri-
nogen III is transferred into the mitochondrial intermembrane
space where it is modified to form protoporphyrinogen IX.
ABCB6 has been proposed to mediate the translocation of
coproporphyrinogen III across the mitochondrial outer mem-
brane (Krishnamurthy et al., 2006), but human patients lacking
ABCB6 have no evidence of anemia or other clinical abnormal-
ities (Helias et al., 2012), making this function unlikely. Fe isCell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc. 319
Figure 1. Mitochondrial Proteins
Containing Fe and Cu
Complexes I–IV of the electron transport chain
require Fe-S clusters, heme moieties, and Cu
centers to function. Complex II functions both in
electron transport and also in the tricarboxylic acid
(TCA) cycle. Complexes I, III, and IV copurify (not
depicted here). Mitochondrial aconitase (ACO2),
another TCA cycle enzyme, contains an Fe-S
cluster. Complex IV acquires Cu from a copper-
ligand pool in the mitochondrial matrix through the
action of cytochrome c oxidase assembly factors
COX17, SCO1, and SCO2. Cu-Zn superoxide
dismutase (SOD1) contains Cu provided by the Cu
chaperone CCS. Mitochondrial ferritin (FTMT) can
store Fe.
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produce heme.
Newly synthesized heme is delivered to various polypeptides
in the cytosol, mitochondria, endoplasmic reticulum, and perox-
isomes. Although several possible mechanisms have been
described for its transport, it is still uncertain how heme leaves
mitochondria to be incorporated into apo-hemoproteins else-
where.
Iron-Sulfur Cluster Biosynthesis and Assembly of Fe-S
Proteins
Fe-S clusters, which are typically coordinated to cysteine or
histidine residues in proteins, serve as cofactors for molecules
involved in electron transfer, catalysis, redox reactions, ribo-
some assembly, DNA damage repair, telomere maintenance,
DNA replication, environmental sensing, and other processes
(for review, see Lill et al., 2012). They are useful and versatile
because Fe and S atoms in the clusters can accept and donate
electrons. Fe-S cluster-containing proteins have important roles
in mitochondria, but they are also found in the cytosol (e.g.,
iron regulatory protein 1, described later) and the nucleus (e.g.,
endonuclease III, involved in base excision repair). The biosyn-
thesis and insertion of Fe-S clusters into extramitochondrial
apo-proteins depends on both mitochondrial and the cytosolic
machinery. Fe-S cluster biosynthesis has been intensively
studied in bacteria and yeast (for review, see Lill et al., 2012),
but the mammalian process and nomenclature are summarized
here (for review, see Rouault, 2012).
Fe-S clusters are transiently assembled on a scaffold (ISCU or
NFU1) in the mitochondrial matrix (Figure 3). A complex of NFS1
and ISD11 provides sulfur appropriated from cysteine (Adam
et al., 2006; Wiedemann et al., 2006). The Fe-binding protein fra-
taxin (FXN) effects a conformational change in ISCU-NFS1 that
promotes cluster formation (Schmucker et al., 2011; Tsai and
Barondeau, 2010). Glutathione has been postulated to be an
Fe source (Hider and Kong, 2011). Fe-glutathione binds to gluta-
redoxins, and one of these, grx5, has been shown to be impor-
tant in mitochondrial Fe-S cluster biosynthesis in the zebrafish320 Cell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc.(Wingert et al., 2005). Fe-S cluster
assembly also requires an electron
procured from NADH via FDXR, FDX1,
and FDX2 proteins (Shi et al., 2012).
Fe-S clusters are released from the scaf-
fold and transferred through a chaperoneprocess to apo-proteins to form new Fe-S proteins. The matura-
tion of aconitase and radical SAMenzymes (e.g., biotin synthase)
requires a complex of A-type scaffold proteins (Gelling et al.,
2008).
Fe-S cluster precursors must be exported to the cytosolic
Fe-S cluster assembly machinery for incorporation into cyto-
plasmic and nuclear apo-proteins. ABCB7 is a transmembrane
transporter important for cytoplasmic Fe-S cluster formation,
but its substrate is unknown (Bekri et al., 2000). A distinct ATP
binding cassette protein, ABCB8, has also been implicated in
Fe-S cluster maturation by a severe phenotype in mice lack-
ing ABCB8 in the heart (Ichikawa et al., 2012). Deficiency of
ABCB8 impairs cytosolic but not mitochondrial Fe-S formation.
While it has been suggested to function as a mitochondrial
iron exporter because decreased expression leads to mitochon-
drial iron accumulation, the precise function of ABCB8 remains
unknown.
Cytoplasmic/Mitochondrial Homeostasis
The inner mitochondrial membrane is impermeable to metal ions
without the aid of dedicated transport systems. Homeostasis
must be maintained in cytoplasmic and mitochondrial metal dis-
tribution to avoid toxicity associated withmetal-induced reactive
oxygen species (ROS) formation. Additionally, mitochondria
must have mechanisms to ensure that cellular metal uptake is
sufficient to meet their needs. These molecular functions are
partially understood.
Fe
Iron can enter cells through direct plasma membrane uptake or
through release from endosomes formed through receptor-
mediated endocytosis of Fe-transferrin bound to cell surface
transferrin receptor (TFRC) (for review, see Andrews, 2008).
Divalent metal transporter 1 (SLC11A2) is important for both
plasma membrane and endosomal transport, though there is
evidence that other molecules can substitute. An unrelated
molecule, ferroportin (SLC40A1), is the only known protein that
can transport iron out of mammalian cells.
Figure 2. Mammalian Heme Biosynthesis
Heme biosynthesis begins and ends in the
mitochondrion, requiring four mitochondrial en-
zymes (d-aminolevulinate synthase, ALAS1/2;
coproporphyrinogen III oxidase, CPOX; proto-
porphyrinogen oxidase, PPOX; and ferrochela-
tase, FECH) and four cytoplasmic enzymes (ALAD,
aminolevulinate dehydratase; PBGD, porphobili-
nogen deaminase; uroporphyrinogen III synthase,
URO3S; and uroporphyrinogen decarboxylase,
UROD). The process is initiated by ALAS, which
catalyzes the production of aminolevulinic acid
from glycine and succinyl coA. Mitoferrin proteins
(SLC25A37 and SLC25A28) transport Fe across
the inner mitochondrial membrane to make it
available for insertion into protoporphyrin IX
by FECH.
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proteins (IRP1 and IRP2) that recognize iron response elements
(IREs) located in untranslated portions of a subset of mRNAs
involved in Fe homeostasis (for review, see Hentze et al.,
2010; Rouault, 2006). These include mRNAs encoding TFRC,
SLC11A2, SLC40A1, and subunits of the iron storage protein
ferritin (FTL and FTH). IRPs act to increase or decrease transla-
tion, depending on the location of IREs within the mRNA. When
cellular Fe is depleted, binding of IRPs to IREs promotes the
synthesis of TFRC and SLC11A2 and inhibits production of
SLC40A1 and ferritin, thus increasing cytoplasmic Fe avail-
ability. Conversely, when cellular Fe is abundant, IRPs are
inactivated, Fe import is restricted, storage is increased, and
export is potentiated. The two IRPs are regulated through
distinct mechanisms: IRP1 is inactivated by incorporation of
a [4Fe-4S] cluster (reviewed by Volz, 2008), whereas IRP2 is
targeted for degradation by a ubiquitin ligase complex that
senses Fe through FBXL5 (Salahudeen et al., 2009; Vashisht
et al., 2009).
Transition metals change oxidation state readily and are
generally bound to proteins to attenuate their reactivity. Although
protein chaperones for Cu have been characterized in great
detail (see below), cytoplasmic Fe chaperone proteins were
not identified until recently. Poly (rC)-binding proteins 1 and 2
(PCBP1 and PCBP2) have been shown to deliver Fe to ferritin
and to a prolyl hydroxylase that regulates hypoxia-inducible
factor 1 (Nandal et al., 2011; Shi et al., 2008). PCBPs have
many homologs, and it is possible that related proteins will simi-
larly turn out to serve as Fe chaperones.
The mitochondrial outer membrane has 2–3 nm pores through
which small molecules can pass freely, but the inner mitochon-
drial membrane is not permeable to metals. Fe is transferredCell Metabolismacross the inner mitochondrial mem-
brane in erythroid and nonerythroid
cells by mitoferrins 1 and 2 (SLC25A37
and SLC25A28), respectively (Paradkar
et al., 2009; Shaw et al., 2006), which
are homologous to the yeast mitochon-
drial Fe transporters Mrs3/4p (Foury and
Roganti, 2002; Mu¨hlenhoff et al., 2003).
An accessory protein, ABCB10, has
been shown to stabilize SLC25A37 during
hemoglobinization of erythroid cells, toensure the high flux of Fe needed for heme biosynthesis (Chen
et al., 2009). No transporters mediating export of mitochondrial
Fe have been definitively identified. It may be that Fe only leaves
the mitochondrion in the form of heme or Fe-S clusters.
Within the mitochondrion Fe has several possible fates: it can
be used to synthesize heme and Fe-S clusters, or incorporated
into mitochondrial ferritin (FTMT; Levi et al., 2001). The normal
function of FTMT is not well understood. Although it is implicated
in sideroblastic anemias (see below), mice lacking Ftmt have no
apparent phenotype (Bartnikas et al., 2010). Overexpression of
FTMT sequesters mitochondrial Fe, making it unavailable for
use (Nie et al., 2005).
Failure of Fe-S cluster biosynthesis alters Fe balance in
mammalian cells (for review, see Lill et al., 2012). Fe-S clusters
act as a switch for IRP1, transforming the IRE-binding pro-
tein into a cytoplasmic aconitase (Rouault, 2006). When Fe-S
cluster biosynthesis is disrupted, IRP1 is constitutively active,
causing cellular Fe to increase. In parallel, heme biosynthesis
is inhibited because active IRP1 inhibits the translation of
ALAS2 and because FECH, the last enzyme in heme biosyn-
thesis, requires a [2Fe-2S] cluster for activity (Wu et al.,
2001). The complex interplay between Fe-S and heme biosyn-
thesis was demonstrated in vivo in zebrafish lacking grx5, a
glutaredoxin necessary for Fe-S cluster production (Wingert
et al., 2005).
Studies of yeast cells lacking FXN and other components of
the Fe-S cluster biogenesis machinery provide insight into cyto-
plasmic/mitochondrial Fe homeostasis (Babcock et al., 1997; Lill
et al., 1999; Rouault and Tong, 2005). The mutant yeast cells are
unable to carry out oxidative phosphorylation, and they activate
a high-affinity Fe uptake system on the plasmamembrane. Total
cellular Fe increases, but the Fe accumulates in mitochondria17, March 5, 2013 ª2013 Elsevier Inc. 321
Figure 3. Mammalian Fe-S Cluster
Biosynthesis
Fe-S cluster biosynthesis is a complex process
that also begins in the mitochondria (see text).
Mitoferrin proteins (SLC25A37 and SLC25A28) are
necessary for Fe procurement. Sulfur is derived by
enzymatic conversion of cysteine to alanine.
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increased mitochondrial Fe, the yeast show increased sensitivity
to oxidative stress.
Fe-S cluster biogenesis may not be as severely affected in
patients with Friedreich’s ataxia or animals carrying FXN muta-
tions. Mitochondrial Fe accumulation has been reported (La-
marche et al., 1980; Puccio et al., 2001), but others suggest
that it is an inconsistent and late finding (Bayot et al., 2011).
However, Fxn-deficient mouse cells do show altered expression
of genes that favor Fe uptake and mitochondrial import over Fe
storage and export (Huang et al., 2009).
Cardiolipin is a phospholipid that is found predominantly in the
inner mitochondrial membrane (Schlame et al., 2000). Defects in
cardiolipin synthesis in human patients lead to Barth Syndrome,
characterized by cardiac and skeletal myopathies and other
abnormalities. Recently it was shown that disruption of cardioli-
pin synthesis in yeast leads to a defect in Fe-S cluster biogen-
esis, most likely due to a failure of mitochondrial import or
processing of proteins involved in Fe-S production (Patil et al.,
2012). Similar to other defects in Fe-S cluster synthesis, this
results in induction of iron uptake genes and mitochondrial iron
accumulation.
When heme biosynthesis is interrupted by treatment with suc-
cinylacetone to inhibit ALAS (the first enzyme of heme biosyn-
thesis), cellular Fe uptake is increased and Fe accumulates in
mitochondria (Ponka et al., 1982).
Taken together, these observations have two important impli-
cations that may be generalizable: (1) that failure of Fe cofactor
biosynthesis triggers excess mitochondrial Fe accumulation
and (2) that mitochondrial Fe needs are communicated to
increase plasma membrane Fe transport. It is an open question
whether other types of mitochondrial dysfunction also lead to
mitochondrial Fe accumulation.322 Cell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc.Cu
Similar to Fe, there are relatively few
proteins known to function as trans-
membrane Cu transporters (for review,
see Wang et al., 2011). There is
one confirmed cellular importer, CTR1
(SLC31A1), which has a close homolog,
CTR2 (SLC31A2), of uncertain function.
Reduction of copper to Cu+ is required
prior to transport. There are two cellular
Cu exporters, ATP7A and ATP7B, both
located predominantly in the trans-
Golgi network. ATP7A can relocate to
the plasma membrane for cellular Cu
export; ATP7B traffics to vesicles and,
among other functions, mediates excre-
tion of Cu into bile. The subcellulartrafficking of CTR1, ATP7A, and ATP7B responds to cellular
copper levels.
There is very little, if any, free Cu within cells: Cu is bound to
proteins or liganded to glutathione or other small molecules.
The problem of making Cu available for cuproenzymes is solved
through the use of Cu chaperones, which bind Cu tightly and
deliver it to target proteins. In mammals, the chaperones are
ATOX1, COX17, and CCS, which deliver Cu to ATP7A/ATP7B,
cytochrome c oxidase and SOD1, respectively (for review, see
Nevitt et al., 2012). Most SOD1 is cytoplasmic, receiving Cu
from CCS without entering the mitochondrion. However, a small
fraction of SOD1 resides in mitochondria, predominantly in
the mitochondrial intermembrane space. Unmetallated CCS
and COX17 are imported into the mitochondrial intermembrane
space through a GFER/MIA40-mediated disulfide relay mecha-
nism (for review, see Herrmann and Riemer, 2012). The entry
of SOD1 into this compartment, as well as its maturation, metal-
lation, and retention, is controlled by CCS (for review, see Kawa-
mata and Manfredi, 2010). The subcellular localization of CCS,
and as a consequence, the subcellular localization of SOD1, is
modulated by oxygen concentration; high oxygen concentration
inhibits import into the mitochondrion (Kawamata and Manfredi,
2008).
COX17 is found both in the cytoplasm and on the inner mito-
chondrial membrane, but translocation is not necessary for its
function, implying that it can receive Cu without having to leave
the mitochondrion (Maxfield et al., 2004). The mitochondrial
source of metal for both CCS and COX17 is a liganded pool of
Cu in the matrix. This pool influences the overall Cu status of
the cell, but the signals responsible have not been identified
(for review, see Leary et al., 2009b). The ligand is not a protein,
but its identity is unknown. It is thought that apo-ligand in the
cytoplasm binds Cu and easily crosses the outer membrane
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ated transport system that is not well understood. Cu-ligand is
retained in the matrix until its Cu is mobilized for use by COX17
or CCS.
COX17, SCO1, and SCO2 are involved in Cu incorporation into
cytochrome c oxidase (Complex IV). Partially oxidized COX17 in
the intermembrane space hands off Cu and two electrons to
oxidized SCO1 (Banci et al., 2008). A homologous protein,
SCO2, has a distinct role. It appears to oxidize Cu-coordinating
cysteines in SCO1 to transfermetal for maturation of cytochrome
oxidase, though the mechanism is not fully understood (Leary
et al., 2009a).
Cells deficient in SCO1 or SCO2 have cytoplasmic Cu defi-
ciency but normal mitochondrial Cu content, suggesting the
existence of homeostatic mechanisms governing Cu distribution
(Dodani et al., 2011). SCO1 and SCO2 also appear to modulate
cellular Cu efflux throughmechanisms not yet understood (Leary
et al., 2009a).
Diseases Associatedwith Failure ofMitochondrial Metal
Homeostasis
Mitochondria are found in all mammalian cells, but they
are particularly abundant in the heart, muscles, and nervous
system, where they support the energy demands of muscle
contraction and neuronal function. Mitochondria also play a crit-
ical role in hemoglobin production in erythroblasts. Accordingly,
erythroid precursors, muscle cells, and neurons are particularly
vulnerable to diseases associated with failure of metal homeo-
stasis and consequent mitochondrial dysfunction. Inborn errors
that affect mitochondrial metal metabolism commonly cause
pathology in more than one of these major target tissues.
Furthermore, the brain is particularly susceptible to increased
oxidative stress and oxidative damage because of its high
rate of oxygen consumption and relatively poor ability to deal
with ROS.
Red Blood Cell Disorders
As discussed earlier, disorders that impair production of heme
and Fe-S clusters trigger homeostatic mechanisms that result
in mitochondrial Fe accumulation. Because red blood cells
require far more heme than other mammalian cells, erythropoi-
esis is particularly sensitive to these defects. The phenotype is
sideroblastic anemia: Fe-laden mitochondria in bone marrow
erythroid precursors and decreased production of circulating
erythrocytes, which may appear Fe deficient. These diseases
typically cause increased intestinal Fe absorption, highlighting
another level of regulation: communication of erythroid needs
to signal alterations in total body Fe homeostasis.
A priori, the fact that there are many steps and many enzymes
involved in heme and Fe-S cluster biosynthesis (Figures 2 and 3)
suggests that sideroblastic anemias will be a heterogeneous set
of disorders due to mutations in a variety of genes. This has
turned out to be the case, and there are still some inherited side-
roblastic anemias for which the cause has not yet been identified
(Fleming, 2011). Interestingly, most defects in heme biosynthetic
enzymes do not cause sideroblastic anemia, but rather result
in porphyrias: diseases associated with the accumulation of
porphyrin intermediates. Although mitochondrial iron accumula-
tion has been reported in the heart, sideroblasts have not been
observed in patients with Friedreich’s ataxia (see below).The most common form of congenital sideroblastic anemia
results from mutations in ALAS2, the rate-limiting, erythroid-
specific form of the first enzyme in heme biosynthesis (Cotter
et al., 1992). Because the ALAS2 gene is on the X chromosome,
this disorder is far more common in males than females. Total
loss of ALAS2 function is probably incompatible with life, and
accordingly, only missense mutations have been described.
ALAS2 uses pyridoxine (vitamin B6) as a cofactor, and many
patients benefit from treatment with pharmacological doses of
the vitamin, distinguishing this form of sideroblastic anemia
from other congenital forms. No mutations in ALAS1, the ubiqui-
tous form of the enzyme, have been described in humans.
A second form of X-linked sideroblastic anemia results from
mutations in ABCB7, a mitochondrial transporter important in
Fe-S cluster formation (Allikmets et al., 1999). The anemia is
milder than in patients with ALAS2 mutations, but accompanied
by ataxia and other neurological manifestations, indicating
an important but as yet undefined role for ABCB7 in the brain.
Recently, ABCB7 was implicated in the pathogenesis of
acquired refractory anemia with ringed sideroblasts (Nikpour
et al., 2012).
Autosomal recessive sideroblastic anemia can also result from
mutations in another gene involved in Fe-S cluster biosynthesis,
GLRX5 (Camaschella et al., 2007). These patients have no mani-
festations other than anemia, possibly because erythroid cells
are uniquely sensitive to perturbations in IRP1 activity resulting
from loss of its Fe-S cluster (Ye et al., 2010). Autosomal reces-
sive sideroblastic anemia is seen in patients with mutations in
SLC25A38, an inner mitochondrial membrane protein with simi-
larity to amino acid transporters, which is predominantly ex-
pressed in hematopoietic cells (Guernsey et al., 2009). Although
it is clear that SLC25A38 is important for heme biosynthesis,
its biological function is unknown. It may be a mitochondrial
importer for glycine, a transporter for 5-aminolevulinic acid, or
perhaps a bifunctional carrier that accomplishes both tasks.
No nonhematopoietic homolog of SLC25A38 has been identi-
fied, but presumably another protein carries out an analogous
function in other cell types.
Recently, Shah and colleagues discovered that a zebrafish
mutant with hypochromic, microcytic red blood cells carried
a mutation in atpif1a resulting in decreased mRNA levels (Shah
et al., 2012). This gene is one of two zebrafish orthologs for
ATPIF1, encoding an inner mitochondrial membrane protein
that modulates the function of the F1F0-ATP synthase. Although
there was no previously described link between ATPIF1 and
heme biosynthesis, themutant zebrafishwere unable to produce
adequate levels of heme for normal erythroid differentiation. The
defect was specific to erythroid cells, presumably because a
homolog, atpif1b, compensates in other cell types, and the
phenotype was replicated in murine cells made deficient in
Atpif1. Atpif1-deficient murine erythroid cells had depletion
of cellular ATP, increased mitochondrial membrane potential,
increased mitochondrial pH, and increased mitochondrial Fe
(Shah et al., 2012). However, in spite of normal amounts of mito-
chondrial protoporphyrin IX, heme was not produced effectively
due to a defect in FECH activity at elevated pH. Pharmacological
agents that lowered mitochondrial membrane potential restored
heme biosynthesis, as did expression of yeast FECH, which
lacks an Fe-S cluster. Their results indicated that, althoughCell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc. 323
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vertebrate FECH is sensitive to mitochondrial changes attribut-
able to deficiency of ATPIF1. Although mutations in ATPIF1
have not yet been found in human patients, erythroid-restricted
loss of function of its gene product would be predicted to be
a cause of sideroblastic anemia.
Autosomal recessive sideroblastic anemia accompanied by
myopathy and lactic acidosis (MLASA disorders) can be caused
by mutations in nuclear genes that are important for overall mito-
chondrial function, including tyrosyl tRNA synthetase-2 (YARS2;
Riley et al., 2010) and pseudouridine synthase (PUS1; Bykhov-
skaya et al., 2004). This phenotype reinforces the concept that
defects in mitochondrial function can alter cytoplasmic/mito-
chondrial Fe homeostasis and lead to mitochondrial Fe loading.
The mitochondrial genome encodes respiratory chain sub-
units, ribosomal RNAs, and tRNAs, andmitochondrial DNA dele-
tions cause pleiotropic abnormalities. PearsonMarrowPancreas
Syndrome, characterized by sideroblastic anemia, pancyto-
penia, and abnormalities of the exocrine pancreas, results from
mitochondrial DNA deletions that may come about during repli-
cation (Ro¨tig et al., 1991). Sideroblastic anemia can also be
caused by toxins and toxic drug effects, as well as deficiencies
of thiamine and Cu.
Cardiomyopathy
Systemic Fe overload results from mutations in hemochroma-
tosis disease genes, from increased Fe absorption secondary
to anemias characterized by ineffective erythropoiesis or from
hypertransfusion of red blood cells. In each of these conditions,
excess Fe accumulates in cardiac myocytes and can cause
cardiomyopathy through promotion of hydroxyl radical forma-
tion, Fe-mediated damage to mitochondrial DNA, and disruption
of the mitochondrial respiratory chain.
Deficiencies of Fe (Petering et al., 1990) and Cu (Klevay, 2000)
have also been associated with mitochondrial dysfunction and
cardiomyopathy in animals, and Fe deficiency has been associ-
ated with cardiomyopathy in humans (Hegde et al., 2006).
However, because Cu deficiency leads to Fe deficiency through
insufficiency of ferroxidases needed for Fe transport, it can be
difficult to tease out how nutritional Cu deficiency results in
specific mitochondrial defects. This has been clarified by
targeted inactivation of the Cu transporter Ctr1 in the mouse
heart. The mutant animals develop severe cardiomyopathy
with abnormal mitochondria and decreased activity of Cu-
containing cytochrome c oxidase (Kim et al., 2010).
Friedreich’s ataxia, caused by decreased expression of active
FXN, is characterized by progressive ataxia and sensory loss
due to neurodegeneration of dorsal root ganglia, cardiomyop-
athy, and sometimes diabetes mellitus. While neurological
impairment may be the most prominent finding, hypertrophic
cardiomyopathy is the most common cause of death. Cardiac
mitochondrial iron accumulation was observed in a small series
many years before FXNwas identified (Lamarche et al., 1980). As
discussed earlier, insufficient expression of this Fe-S cluster
pathway protein leads tomitochondrial failure, and dysfunctional
mitochondria proliferate at the expense of muscle fibers (for
review, see Payne and Wagner, 2012).
Cardiomyopathy is also a prominent feature of fatal infantile
cardioencephalopathy, due to cytochrome c oxidase deficiency
resulting from mutations in the mitochondrial Cu chaperone324 Cell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc.protein SCO2 (Papadopoulou et al., 1999). Interestingly, most
or all patients identified to date have at least one allele carrying
an E140K mutation (Leary et al., 2007), which disrupts a salt
bridge close to the CXXC Cu binding motif. Although there is
a profound loss of motor neurons resulting in hypotonia and
weakness, death is typically caused by heart failure. Cu content
of the heart ismarkedly reduced as a result of increased Cu efflux
(Leary et al., 2007). SCO1 is a close homolog of SCO2, but muta-
tions in SCO1 cause a different disorder, with hepatic failure and
death soon after birth (Valnot et al., 2000). Accordingly, SCO
proteins have distinct roles in cytochrome c oxidase maturation
(Leary et al., 2009a).
Cardiomyopathy is a severe consequence of inactivation of
the gene encoding Mn-dependent, mitochondrial SOD2 gene
in mice (Li et al., 1995). The mutant animals are anemic, with
metabolic acidosis and lipid accumulation in the liver and
muscle, and death before the end of the second week of life.
Activity of two Fe-S-requiring enzymes, succinate dehydroge-
nase (complex II) and aconitase, is markedly reduced, suggest-
ing that inadequate defense against nondismutated O2
 in
mitochondria leads to destruction of Fe-S clusters, compro-
mising the electron transport chain and the TCA cycle. The heart
may be less able to deal with oxidative stress than other organs.
Skeletal Myopathy
Abnormalities of mitochondrial metal homeostasis can also
cause disorders of skeletal muscle, with or without abnormalities
in other tissues. In addition to disorders described earlier, myop-
athies not accompanied by sideroblastic anemia are caused by
mutations in several genes responsible for Fe-S cluster biogen-
esis. Deficiency of the scaffold protein ISCU, due to a splicing
error, causes autosomal recessive myopathy with mitochondrial
Fe overload (Mochel et al., 2008; Olsson et al., 2008). Interest-
ingly, the aberrant splicing event appears to be restricted to
skeletal muscle; normal splicing is favored in cardiomyocytes,
hepatocytes, and very likely in erythroid precursors (Crooks
et al., 2012; Nordin et al., 2011).
Global Mitochondrial Dysfunction
Four infants in two unrelated families were reported to have lactic
acidosis and multisystem mitochondrial pathology leading to
death in the first year of life (Seyda et al., 2001). This disorder,
termed multiple mitochondrial dysfunctions syndrome, showed
linkage to chromosome 2p14-2p13. Surprisingly, although the
phenotypes were similar, the two families carried deleterious
mutations in different genes, NFU1 and BOLA3, located 5 Mbp
apart (Cameron et al., 2011). Other groups identified mutations
in NFU1 (Navarro-Sastre et al., 2011) and BOLA3 (Haack et al.,
2012) in distinct families with phenotypic similarity.
NFU1 is known to be important in Fe-S cluster biogenesis and
has been postulated to act as a scaffold in a pathway parallel to
the ISCU scaffold (Figure 3; Tong et al., 2003). A severe defect
in Fe-S cluster synthesis would explain the dramatic clinical
presentation and deficiencies inmitochondrial electron transport
complexes observed in these patients (Cameron et al., 2011;
Navarro-Sastre et al., 2011). In contrast, the role of BOLA3 was
not previously known, although homologs have been reported
to act as reductases interacting with a glutaredoxin (Huynen
et al., 2005) and to affect iron homeostasis in yeast (Li et al.,
2011). Taken together with clinical and biochemical phenotypes
similar to those observed in a patient withNFU1mutation, a likely
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Fe-S synthesis.
There are many rare genetic disorders, e.g., Leigh syndrome,
resulting from defects in proteins involved in the formation and/
or function of the mitochondrial respiratory chain (for review, see
Wong, 2012). Although all tissues should be affected, these
early-onset disorders typically have neurodegeneration as the
most prominent feature and, sometimes, cardiomyopathy and
muscle disease. A subset have mutations in proteins containing
or involved in insertion of heme (e.g., COX10 [Antonicka et al.,
2003], COX15 [Bugiani et al., 2005], and SURF1 [Bundschuh
et al., 2009]) or Fe-S clusters (e.g., NDUFV1 [Vilain et al., 2012],
NDUFS3 [Be´nit et al., 2004], NUBPL [Calvo et al., 2010], and
NDUFS8 [Loeffen et al., 1998]).
Neurodegenerative Diseases
The brain needs far more energy than other organs, necessi-
tating optimal ATP production by neurons. Many neurode-
generative diseases are associated with both mitochondrial
dysfunction and metal deposition in the vicinity of brain
lesions, but in general the pathogenesis is unclear. Several key
proteins associated with neurodegenerative diseases have
been reported to have intimate connections to transition metals.
Amyloid precursor protein (APP) was reported to have an
intrinsic ferroxidase activity (Duce et al., 2010), although other
investigators have not observed this (Ebrahimi et al., 2012).
Alpha-synuclein (SNCA) and prion protein (PRNP) assemble
into metal-containing aggregates. Although APP, SNCA, and
PRNP are not known to be directly involved in mitochondrial
metal metabolism, mitochondrial quality and quality control are
strongly implicated in the neurodegenerative diseases with
which they are associated.
Neurodegeneration with brain Fe accumulation (NBIA) disor-
ders are distinguished by characteristic Fe accumulation in the
basal ganglia visualized by magnetic resonance imaging and
obvious brown (Fe) discoloration of the brain on autopsy. The
gene most commonly mutated in NBIA, pantothenate kinase 2
(PANK2), encodes an enzyme important for mitochondrial coen-
zyme A biosynthesis (Zhou et al., 2001). Other genes mutated in
NBIA patients include a novel mitochondrial protein, C19orf12,
possibly also involved in coenzyme A metabolism (Hartig et al.,
2011).
Neurodegeneration with impaired mitochondrial function in
motor neurons has been reported in Ireb2/ mice lacking
IRP2 (Jeong et al., 2011). Abnormal cellular Fe homeostasis
results in decreased complex I and II activity in the mitochondria
of lower motor neurons, apparently because of inappropriate
regulation resulting in decreased expression of Tfrc and in-
creased storage of iron in ferritin. Accordingly, the phenotype
was ameliorated by a genetic maneuver to decrease ferritin
production. Taken together, these results suggest that cellular
Fe deficiency can also cause neuronal degeneration.
The gene encoding Cu-Zn SOD1 is mutated in a subgroup of
patients with familial amyotrophic lateral sclerosis (ALS), and
mitochondrial dysfunction is a common feature of both genetic
and sporadic forms of the disease. SOD1 mutations are consid-
ered to be gain-of-function, and the mutant protein preferentially
accumulates in themitochondrial intermembrane space. Various
models for toxic gain-of-function mutations have been pro-
posed, involving increased production of ROS and Ca2+ dysre-gulation (for review, see Faes and Callewaert, 2011), but the
pathophysiology is still unresolved.
Much remains to be learned about metals, mitochondria, and
neurodegenerative diseases. There is substantial overlap in clin-
ical presentation and pathologic features among these disor-
ders, but there is still uncertainty about cause and effect. Does
mitochondrial dysfunction lead to metal accumulation, or does
metal accumulation lead to ROS production and mitochondrial
dysfunction? Are protein-metal aggregates causing mitochon-
drial dysfunction and neurodegeneration, or are they a marker
of neurodegeneration, or both?
Conclusions
The relationship between metals and mitochondria has been
studied for decades, but much remains to be learned. Our
current understanding relies heavily on elegant studies in yeast
and on inborn errors of metabolism in human patients. Fully
elucidating the interaction between metals and mitochondria in
disease will require new approaches, but it will undoubtedly
enrich our understanding of mitochondrial biology.
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